Pharmacokinetic behavior and antineoplastic activity of liposomal hexadecylphosphocholine

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/BF00685563PMID 8070005
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Liposomal Hexadecylphosphocholine: Characterization and Effects on Adherent Tumor Cells.

  2008cited by this paper
• Heterogeneity of biotransformation of fluoranthene in perifused liver cells

  2004cited by this paper
• Alkylphosphocholines: influence of structural variation on biodistribution at antineoplastically active concentrations

  2004cited by this paper
• Stability of Liposomes in Vitro and Their Uptake by Rat Peyer's Patches Following Oral Administration

  1993cited by this paper
• Hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine: a comparison of hemolytic activity, serum binding and tissue distribution.

  1992cited by this paper
• Hexadecylphosphocholine in liposomal dispersions.

  1992cited by this paper
• Synthesis of hexadecylphosphocholine (miltefosine).

  1992cited by this paper
• Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice

  1992cited by this paper
• Effects of hexadecylphosphocholine on cellular function.

  1992cited by this paper
• Antitumor activity of alkylphosphocholines and analogues in methylnitrosourea-induced rat mammary carcinomas.

  1992cited by this paper
• Hexadecylphosphocholine amplifies the effect of granulocyte colony-stimulating factor on differentiating hematopoietic progenitor cells.

  1992cited by this paper
• Determination of alkylphosphocholines and of alkyl-glycero-phosphocholines in biological fluids and tissues.

  1992cited by this paper
• Effectiveness of liposomes as adjuvants of orally and nasally administered tetanus toxoid

  1992cited by this paper
• Liposomes Enhance the Oral Availability of Certain Water‐Insoluble Drugs

  1991cited by this paper
• Proliposomes of indomethacin for oral administration.

  1991cited by this paper
• Hexadecylphosphocholine: Preclinical and the first clinical results of a new antitumor drug

  1991cited by this paper
• Hexadecylphosphocholine inhibits inositol phosphate formation and protein kinase C activity.

  1991cited by this paper
• Effects of hexadecylphosphocholine on protein kinase C and TPA-induced differentiation of HL60 cells

  1991cited by this paper
• Hexadecylphosphocholine: determination of serum concentrations in rats.

  1991cited by this paper
• Hexadecylphosphocholine (D-18506): A New Phospholipid with Highly Selective Antitumor Activity

  1990cited by this paper
• Hexadecylphosphocholine: a new and selective antitumor drug.

  1990cited by this paper
• Cytotoxic activity of lysophosphatidylcholine analogues on human lymphoma Raji cells.

  1990cited by this paper
• New cytostatics--more activity and less toxicity.

  1990cited by this paper
• Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients.

  1990cited by this paper
• Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo.

  1989cited by this paper
• Characterization of the antitumor activity of hexadecylphosphocholine (D 18506).

  1988cited by this paper
• Hexadecylphosphocholine (D 18506) in the topical treatment of skin metastases: a phase-I trial.

  1988cited by this paper
• Etherlipids in the topical treatment of skin metastases.

  1988cited by this paper
• Encapsulation of indomethacin in liposomes provides protection against both gastric and intestinal ulceration when orally administered to rats.

  1988cited by this paper
• Synthetische Alkyllysophospholipide als Antitumormittel ‐ Strukturverwandte des „Platelet Activating Factors”︁

  1988cited by this paper
• Metabolism of ether phospholipids and analogs in neoplastic cells

  1987cited by this paper
• New cytostatics with experimentally different toxic profiles.

  1987cited by this paper
• Gastrointestinal uptake of liposomes. I. In vitro and in situ studies

  1987cited by this paper
• Gastrointestinal uptake of liposomes. II. In vivo studies

  1987cited by this paper
• Alkyl phosphocholines: Toxicity and anticancer properties

  1987cited by this paper
• Transmucosal Passage of Liposomally-Entrapped Drugs in Rat Small Intestine

  1984cited by this paper
• Noncarcinogenic chemotherapy with a combination of vincristine, methotrexate and 5‐fluorouracil (VMF) in rats

  1983cited by this paper
• Can intact liposomes be absorbed in the gut?

  1981cited by this paper
• The stability of liposomes in vitro to pH, bile salts and pancreatic lipase.

  1980cited by this paper
• A new method for preparation of phospholipid vesicles (liposomes) ‐ french press

  1979cited by this paper

• Evaluation of release and pharmacokinetics of hexadecylphosphocholine (miltefosine) in phosphatidyldiglycerol-based thermosensitive liposomes.

  2021cites this paper
• Preparation, Pharmacokinetics, and Antitumor Potential of Miltefosine-Loaded Nanostructured Lipid Carriers

  2021cites this paper
• Synthesis and Evaluation of Antitumor Alkylphospholipid Prodrugs

  2020cites this paper
• Development, In vitro and In vivo Evaluation of Miltefosine Loaded Nanostructured Lipid Carriers for the Treatment of Cutaneous Leishmaniasis.

  2020cites this paper
• Erufosine (ErPC3) Cationic Prodrugs as Dual Gene Delivery Reagents for Combined Antitumor Therapy.

  2019cites this paper
• Incorporation of the antitumor drug miltefosine into polymeric micelles

  2019cites this paper
• Alkylphospholipids are Signal Transduction Modulators with Potential for Anticancer Therapy.

  2019cites this paper
• Pharmacokinetics and bioavailability assessment of Miltefosine in rats using high performance liquid chromatography tandem mass spectrometry.

  2016cites this paper
• Miltefosine-loaded lipid nanoparticles: Improving miltefosine stability and reducing its hemolytic potential toward erythtocytes and its cytotoxic effect on macrophages.

  2016cites this paper
• Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma.

  2015cites this paper
• Apoptosis induction by erucylphosphohomocholine via the 18 kDa mitochondrial translocator protein: implications for cancer treatment.

  2014cites this paper
• Miltefosina oral para el tratamiento de la leishmaniasis

  2012cites this paper
• Efficacy and tolerability of oleylphosphocholine (OlPC) in a laboratory model of visceral leishmaniasis.

  2012cites this paper
• Miltefosine loaded albumin microparticles for treatment of visceral leishmaniasis: formulation development and in vitro evaluation

  2011cites this paper
• Cellular transport and lipid interactions of miltefosine.

  2009cites this paper
• Lipid-based nanoparticulate systems for the delivery of anti-cancer drug cocktails: Implications on pharmacokinetics and drug toxicities.

  2009cites this paper
• In-vitro-Untersuchungen zur Kombinationswirkung von

  2008cites this paper
• Novel approaches to assess the efficacy and toxicity of intestinal absorption enhancers

  2006cites this paper
• Miltefosine: oral treatment of leishmaniasis

  2006cites this paper
• In Vitro and In Vivo Interactions between Miltefosine and Other Antileishmanial Drugs

  2006cites this paper
• The influence of subphase temperature on miltefosine-cholesterol mixed monolayers.

  2006cites this paper
• Structure-activity relationships of antineoplastic ring-substituted ether phospholipid derivatives

  2005cites this paper
• Cytotoxic Activities of Alkylphosphocholines against Clinical Isolates of Acanthamoeba spp

  2002cites this paper
• A lysophosphatidic acid analogue is revealed as a potent inhibitor of phosphatidylcholine synthesis, inducing apoptosis.

  2002cites this paper
• Effects of Miltefosine and Other Alkylphosphocholines on Human Intestinal ParasiteEntamoeba histolytica

  2001cites this paper
• Erucylphosphocholine: pharmacokinetics, biodistribution and CNS-accumulation in the rat after intravenous administration

  1999cites this paper
• Pharmacokinetics of sterically stabilized hexadecylphosphocholine liposomes versus conventional liposomes and free hexadecylphosphocholine in tumor-free and human breast carcinoma bearing mice

  1999cites this paper
• Bcl-2 plays a key role instead of mdr1 in the resistance to hexadecylphosphocholine in human epidermoid tumor cell line KB.

  1999cites this paper
• The potential of liposomes in oral drug delivery.

  1998cites this paper
• Antitumor effects of erucylphosphocholine on brain tumor cells in vitro and in vivo.

  1998cites this paper
• Physical properties and pharmacological activity in vitro and in vivo of optimised liposomes prepared from a new cancerostatic alkylphospholipid.

  1998cites this paper
• Stability of association of 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine with liposomes is composition dependent.

  1997cites this paper
• Alkylphosphocholines induce apoptosis in HL-60 and U-937 leukemic cells

  1997cites this paper
• Pharmacokinetics of N4‐Octadecyl‐1‐β‐d‐Arabinofuranosylcytosine in Plasma and Whole Blood after Intravenous and Oral Administration to Mice

  1997cites this paper
• Systemic administration of alkylphosphocholines. Erucylphosphocholine and liposomal hexadecylphosphocholine.

  1996cites this paper